A detailed history of Ubs Group Ag transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Ubs Group Ag holds 168,374 shares of ABUS stock, worth $535,429. This represents 0.0% of its overall portfolio holdings.

Number of Shares
168,374
Previous 55,665 202.48%
Holding current value
$535,429
Previous $172,000 276.74%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $4.56 $351,652 - $513,953
112,709 Added 202.48%
168,374 $648,000
Q2 2024

Aug 13, 2024

SELL
$2.52 - $3.63 $199,478 - $287,343
-79,158 Reduced 58.71%
55,665 $172,000
Q1 2024

May 13, 2024

SELL
$2.26 - $2.92 $11,634 - $15,032
-5,148 Reduced 3.68%
134,823 $347,000
Q4 2023

Feb 09, 2024

BUY
$1.69 - $2.54 $130,726 - $196,476
77,353 Added 123.53%
139,971 $349,000
Q3 2023

Nov 09, 2023

SELL
$1.9 - $2.27 $10,543 - $12,596
-5,549 Reduced 8.14%
62,618 $127,000
Q2 2023

Aug 11, 2023

BUY
$2.24 - $3.06 $70,564 - $96,396
31,502 Added 85.92%
68,167 $156,000
Q1 2023

May 12, 2023

BUY
$2.23 - $3.1 $29,828 - $41,465
13,376 Added 57.43%
36,665 $111,000
Q4 2022

Feb 08, 2023

BUY
$1.91 - $2.85 $44,481 - $66,373
23,289 New
23,289 $54,000
Q2 2022

Aug 10, 2022

SELL
$1.98 - $3.17 $2,570 - $4,114
-1,298 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $79,400 - $130,583
-32,810 Reduced 96.19%
1,298 $4,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $106,075 - $157,237
34,108 New
34,108 $132,000
Q3 2021

Nov 15, 2021

SELL
$2.65 - $4.62 $165,121 - $287,872
-62,310 Closed
0 $0
Q2 2021

Aug 13, 2021

SELL
$2.5 - $3.51 $27,012 - $37,925
-10,805 Reduced 14.78%
62,310 $189,000
Q1 2021

May 12, 2021

BUY
$3.14 - $4.84 $173,293 - $267,114
55,189 Added 307.87%
73,115 $244,000
Q4 2020

Feb 11, 2021

BUY
$2.76 - $4.97 $30,119 - $54,237
10,913 Added 155.61%
17,926 $64,000
Q3 2020

Nov 12, 2020

SELL
$1.75 - $6.2 $555,238 - $1.97 Million
-317,279 Reduced 97.84%
7,013 $22,000
Q2 2020

Jul 31, 2020

SELL
$0.91 - $2.36 $41,728 - $108,220
-45,856 Reduced 12.39%
324,292 $590,000
Q1 2020

May 01, 2020

BUY
$1.01 - $3.42 $128,199 - $434,100
126,930 Added 52.19%
370,148 $374,000
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $49,671 - $165,001
57,094 Added 30.68%
243,218 $676,000
Q3 2019

Nov 14, 2019

BUY
$1.34 - $2.4 $26,418 - $47,316
19,715 Added 11.85%
186,124 $284,000
Q2 2019

Aug 14, 2019

BUY
$1.46 - $4.44 $234,549 - $713,286
160,650 Added 2789.55%
166,409 $346,000
Q1 2019

May 14, 2019

BUY
$3.41 - $4.57 $3,935 - $5,273
1,154 Added 25.06%
5,759 $21,000
Q4 2018

Feb 14, 2019

BUY
$3.5 - $9.66 $11,263 - $31,085
3,218 Added 232.01%
4,605 $18,000
Q3 2018

Nov 14, 2018

SELL
$7.85 - $12.35 $285,543 - $449,231
-36,375 Reduced 96.33%
1,387 $13,000
Q2 2018

Aug 14, 2018

SELL
$5.0 - $7.35 $21,015 - $30,892
-4,203 Reduced 10.02%
37,762 $276,000
Q1 2018

May 15, 2018

SELL
$4.4 - $6.05 $10,542 - $14,495
-2,396 Reduced 5.4%
41,965 $210,000
Q4 2017

Feb 14, 2018

SELL
$4.45 - $7.7 $36,512 - $63,178
-8,205 Reduced 15.61%
44,361 $224,000
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $178,333 - $367,157
52,451 Added 45609.57%
52,566 $326,000
Q2 2017

Aug 14, 2017

SELL
N/A
-1,739 Reduced 93.8%
115 $0
Q1 2017

Nov 14, 2017

BUY
N/A
1,854
1,854 $6,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $477M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.